Non-alcoholic steatohepatitis

April 18, 2017April 19, 2017

Albireo Hosts NYC Breakfast to Discuss A4250 Therapy for Pediatric Liver Diseases

Boston-based Albireo Pharma hosted an April 13 breakfast presentation in New York that featured an overview of the company’s clinical programs as well as a talk by pediatric liver specialist Philip Rosenthal, MD, about ... Read more

April 17, 2017April 19, 2017

Galectin Plans to Present Data from Phase 2 NASH Cirrhosis Trial by Year’s End

Liver cirrhosis, News, Non-alcoholic steatohepatitis

Galectin Therapeutics’s lead drug GR-MD-02 may be a promising therapeutic approach to treat fibrosis in fatty liver disease — or non-alcoholic steatohepatitis (NASH) — based on results from a Phase 1 study. The company is ... Read more

April 11, 2017April 11, 2017

Conatus Discusses Its Liver Disease Therapy Emricasan at Two New York Events

Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Conatus Pharmaceuticals updated participants at two New York medical conferences this month on its efforts to develop emricasan, which has been shown to improve manifestations of chronic kidney disease. The San Diego-based ... Read more

April 10, 2017April 19, 2017

Statins May Be Option for Treating Chronic Liver Disease, Study Suggests

News, Non-alcoholic steatohepatitis

A new review suggests that statins — used primarily to manage cholesterol — may be effective in treating liver inflammation and chronic liver disease. Statins are often prescribed to people at high ... Read more

March 30, 2017April 5, 2017

CymaBay Continues Development of Seladelpar for Liver Disease as Interim President, CEO Named

News, Non-alcoholic steatohepatitis

CymaBay Therapeutics has named Sujal Shah as interim president and CEO following the retirement of Harold Van Wart, PhD. Robert Wills, PhD, will serve as executive chairman during this transition phase. California-based ... Read more

March 28, 2017March 30, 2017

Changes in Gut Microbiota Can Aid Liver and Work to Counter Obesity, Mouse Study Shows

News, Non-alcoholic steatohepatitis

Dysbiosis, an imbalance in the proportion and activity of bacterial groups of the gut microbiota, can actually aid in liver metabolism and protect the body against diseases that include obesity, new ... Read more

March 13, 2017March 30, 2017

Study Reveals How Fatty Liver Disease May Progress to NASH

News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

The tiny spheres, or microvesicles (MVs), released from liver cells and macrophages seem to be key players in the progression of non-alcoholic fatty liver disease (NAFLD) into non-alcoholic steatohepatitis (NASH). ... Read more